Chapter: Restrictive Cardiomyopathy
McMaster Section Editor(s): P.J. Devereaux
Section Editor(s) in Interna Szczeklika: Andrzej Budaj, Wiktoria Leśniak
McMaster Author(s): Harriette G.C. Van Spall, Shoeb Ahsan
Author(s) in Interna Szczeklika: Jan Wodniecki, Wiktoria Leśniak
How to Cite This Chapter: Van Spall HGC, Ahsan S, Wodniecki J, Leśniak W. Restrictive Cardiomyopathy. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.II.2.16.3 Accessed July 21, 2019.
Last Reviewed: July 4, 2018
Last Updated: July 4, 2018
Main Documents Taken Into Account:
Bozkurt B, Colvin M, Cook J, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.
Circulation. 2016 Dec 6;134(23):e579-e646. Epub 2016 Nov 3. Erratum in: Circulation. 2016 Dec 6;134(23):e652. PubMed PMID: 27832612.
WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435. Epub 2016 May 20. Erratum in: Circulation. 2016 Sep 27;134(13):e298. PubMed PMID: 27208050.
Ponikowski P, Voors AA, Anker SD, et al; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur Heart J. 2016 Jul 14;37(27):2129-200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30. PubMed PMID: 27206819.
Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives.
Eur Heart J. 2015 May 7;36(18):1090-7. doi: 10.1093/eurheartj/ehv009. Epub 2015 Jan 29. Review. PubMed PMID: 25636745; PubMed Central PMCID: PMC4422973.
Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29. PubMed PMID: 25173338.
Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases.
Eur Heart J. 2013 May;34(19):1448-58. doi: 10.1093/eurheartj/ehs397. Epub 2012 Dec 4. PubMed PMID: 23211230.
Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation. 2011 Dec 13;124(24):2761-96. doi: 10.1161/CIR.0b013e318223e230. Epub 2011 Nov 8. PubMed PMID: 22068435.
Charron P, Arad M, Arbustini E, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur Heart J. 2010 Nov;31(22):2715-26. doi: 10.1093/eurheartj/ehq271. Epub 2010 Sep 7. PubMed PMID: 20823110.
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur Heart J. 2008 Jan;29(2):270-6. Epub 2007 Oct 4. PubMed PMID: 17916581.
Maron BJ, Towbin JA, Thiene G, et al; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.
Circulation. 2006 Apr 11;113(14):1807-16. Epub 2006 Mar 27. PubMed PMID: 16567565.
Definition, Etiology, PathogenesisTop
Restrictive cardiomyopathy (RCM) is a disease of the myocardium characterized mainly by left ventricular (LV) diastolic dysfunction. RCM may be familial (eg, inherited defects in desmin or troponin I) or caused by systemic disorders (eg, amyloidosis, sarcoidosis, scleroderma, carcinoid disease, radiation, and endomyocardial fibrosis caused by hypereosinophilic syndrome or drugs such as serotonin or ergotamine).
Clinical Features and Natural HistoryTop
Manifestations of RCM include dyspnea, fatigue, and in more advanced disease also features of right ventricular dysfunction. The natural history of RCM largely depends on its etiology and severity of myocardial changes.
1. Electrocardiography (ECG) may reveal abnormal P waves, a low R-wave amplitude, flat T waves, and supraventricular arrhythmias, especially atrial fibrillation. In amyloid cardiomyopathy, ECG typically has low voltages due to infiltration of amyloid.
2. Echocardiography may reveal normal or increased LV wall thickness, enlargement of both atria with relatively small ventricles, normal or slightly impaired systolic function of the ventricles, and diastolic LV dysfunction. Tissue Doppler echocardiography can be useful to differentiate between RCM and constrictive pericarditis.
3. Heart catheterization is performed in case of difficulties in differentiating between RCM and constrictive pericarditis.
4. Endomyocardial biopsy is performed in the case of suspected myocardial infiltrates caused by amyloidosis, sarcoidosis, idiopathic eosinophilia, or hemochromatosis.
5. Cardiac magnetic resonance imaging (MRI) may be useful in differentiating underlying etiologies such as sarcoidosis, amyloidosis, endomyocardial fibrosis, or eosinophilia.
6. Cardiac 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) may be useful in the diagnosis and assessment of treatment response in sarcoidosis.
RCM is diagnosed on the basis of imaging studies and in some cases on the basis of histologic examination of cardiac biopsy specimens.
RCM should be mainly differentiated from constrictive pericarditis. This usually requires a specialized cardiology assessment and may involve invasive testing.
1. Symptomatic treatment: As in chronic heart failure.
2. Long-term anticoagulation is used in patients with atrial fibrillation.
3. Heart transplantation is used in end-stage heart failure not responding to treatment.
4. Treatment of the underlying condition is used in patients with potentially reversible causes.
1. Cardiomyopathy associated with hemochromatosis may lead to heart failure but frequently causes only minor symptoms. Treatment is with phlebotomy.
2. Cardiomyopathy associated with amyloidosis develops in 50% of patients with AL amyloidosis, 10% of patients with AA amyloidosis, and rarely in those with familial disease. Amyloid deposits lead to significant cardiac dysfunction and wall thickening, causing features of restriction and diastolic LV dysfunction, as well as to reduced right ventricular function. Amyloidosis also leads to arrhythmia, conduction disease, and a tendency to orthostatic hypotension. It must be suspected in the case of RCM developing in a person with proteinuria, hepatomegaly, anemia, or a chronic inflammatory condition. Echocardiographic features include marked hypertrophy of the ventricles, diastolic dysfunction with or without LV systolic dysfunction, biatrial enlargement, interatrial hypertrophy, and pericardial effusion. Diagnosis may be confirmed with biopsy of the abdominal fat pad, gingiva, rectum, or affected organ. Chemotherapy is available for patients with AL amyloidosis associated cardiomyopathy. Caution is noted with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, digoxin, beta-blockers, and calcium channel blockers, given their predisposition to cause hypotension in patients with this disease. Beta-blockers can be used, however, in the context of atrial fibrillation to improve diastolic filling time. Otherwise, careful use of diuretics is the pharmacotherapy of choice.